Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NCS1 | P62166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18094514 | 0.88 | THRB (0.45) | MAPTSMN1; SMN2ADORA3 | |
| SCHEMBL18094584 | 0.85 | MAPT (0.53) | MAPTNPC1TP53SMN1; SMN2ADORA3 | |
| SCHEMBL18094572 | 0.84 | MAPT (0.53) | MAPTNPC1TP53SMN1; SMN2ADORA3 | |
| SCHEMBL18094494 | 0.83 | TLR7 (0.54) | ADORA3RXFP1 | |
| SCHEMBL18230494 | 0.80 | NPC1 (0.49) | MAPTNPC1KLF5TP53SMN1; SMN2 | |
| SCHEMBL18094537 | 0.80 | ADORA3 (0.53) | MAPTNPC1ADORA3RAB9A | |
| SCHEMBL18805810 | 0.79 | MPL (0.52) | MAPTTP53ADORA3LMNA | |
| SCHEMBL18094560 | 0.79 | MAPT (0.59) | MAPTNPC1TP53SMN1; SMN2ADORA3 | |
| SCHEMBL18094502 | 0.78 | ADORA3 (0.71) | MAPTNPC1SMN1; SMN2ADORA3RAB9A | |
| SCHEMBL18805807 | 0.77 | POLB (0.42) | MAPTTP53ADORA3LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | AVISTA PHARMA SOLUTIONS, INC. | 2017-07-20 | — | — | US | claimed |
| US-9643963-B2 | Antiparasitic compounds | AVISTA PHARMA SOLUTIONS, INC. (US) | 2017-05-09 | — | — | US | claimed |
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | SNAPDRAGON CHEMISTRY, INC. | 2016-09-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | MAPT 2921/4885NPC1 1220/4885KLF5 4176/4885 |
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | MAPT 2921/4885NPC1 1220/4885KLF5 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.